Can Insurers Curb Opioid Abuse? CDC Puts Spotlight On Payers
This article was originally published in The Pink Sheet Daily
Executive Summary
As Medicare emerges as the dominant payer for opioids, CDC urges research into how government and private payers could best employ prior authorization and drug utilization reviews.
You may also be interested in...
NIH Advisors Back Insuring Complementary, Alternative Solutions To Drugs For Health Care
Consumers with chronic pain spend less in co-pays for pain medications than they would for natural remedies or treatments such as chiropractic or acupuncture because few insurance plans pay for alternative care, NIH advisory committee members say.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.